Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Nasopharyngeal Carcinoma × Population Groups × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Neoplasms 3 Hemangioma, Capillary 2 Anxiety Disorders 2 Weight Loss 1 Vomiting 1 Urinary Incontinence, Stress 1 Urinary Incontinence 1 Urinary Bladder Neoplasms 1 Shoulder Pain 1 Respiratory Aspiration 1 Psychomotor Agitation 1 Prostatic Neoplasms 1 Premature Birth 1 Polycystic Ovary Syndrome 1 Pediatric Obesity 1 Pancreatic Neoplasms 1 Pain, Postoperative 1 Ovarian Cysts 1 Obesity 1 Neuromuscular Diseases 1 Nasopharyngeal Carcinoma 1 Myofibroma 1 Myelodysplastic Syndromes 1 Myasthenia Gravis 1 Multiple Myeloma 1 Menstruation Disturbances 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Liver Cirrhosis 1

Interventions

Cisplatin 99 Radiotherapy, Intensity-Modulated 55 Gemcitabine 50 toripalimab 30 Docetaxel 30 Fluorouracil 29 Capecitabine 26 Radiotherapy 20 Drug Therapy 18 nimotuzumab 16 camrelizumab 16 nedaplatin 12 apatinib 11 Induction Chemotherapy 11 sintilimab 10 Chemoradiotherapy 10 spartalizumab 9 tislelizumab 7 pembrolizumab 7 endostar protein 7 Paclitaxel 7 Immune Checkpoint Inhibitors 7 Endostatins 7 Cetuximab 7 Bevacizumab 7 fludarabine 5 Radiation 5 Endoscopy 5 Cyclophosphamide 5 fludarabine phosphate 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01536223 2013-03-05

ESNCCT

Zhejiang Cancer Hospital

Phase 3 Unknown

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡